A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Aulos Bioscience, Inc.
AstraZeneca
Mayo Clinic
Neonc Technologies, Inc.
Tasca Therapeutics
University of California, Davis
Ocellaris Pharma, Inc.
Inhibrx Biosciences, Inc
Tanabe Pharma America, Inc.
DualityBio Inc.
BicycleTx Limited
University of Pittsburgh
Dragonfly Therapeutics
Scancell Ltd
GI Innovation, Inc.
A2 Biotherapeutics Inc.
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Mural Oncology, Inc
Klus Pharma Inc.
Kymab Limited
Portage Biotech
RAPT Therapeutics, Inc.
ImmunoGenesis
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
GlaxoSmithKline
Pfizer
NextCure, Inc.
Evopoint Biosciences Inc.
Fusion Pharmaceuticals Inc.
Rain Oncology Inc
Genmab
Nektar Therapeutics
Rubius Therapeutics
Ludwig Institute for Cancer Research
Incyte Corporation
Genocea Biosciences, Inc.
Silverback Therapeutics
Seagen Inc.
Incyte Corporation
NKGen Biotech, Inc.
Incyte Corporation
Celldex Therapeutics
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center